Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

October 12, 2006 07:50 ET

Media Advisory: Ambrilia and Merck & Co. Conclude Licensing Agreement

MONTREAL, QUEBEC--(CCNMatthews - Oct. 12, 2006) - Mr. Hans J. Mader, President and Chief Executive Officer of Ambrilia Biopharma Inc. (TSX:AMB) invites the news media to attend a press conference pursuant to the licensing agreement concluded with Merck & Co., Inc., under which Ambrilia grants Merck the exclusive worldwide rights to its lead HIV/AIDS product, PPL-100.

DATE AND TIME: Thursday, October 12, 2006, 10:30 a.m.
WHERE: Ambrilia Biopharma, 1000 Chemin du Golf, Verdun


Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing innovative and proprietary early- to mid-stage therapeutics in the fields of oncology and infectious diseases. Ambrilia's product portfolio includes an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of which is late-stage and value-added, and promising anti-HIV treatments (PPL-100, Anti-HIV Peptides, Integrase Inhibitor Program). Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site:

Forward-looking statement

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward-looking statements.

Contact Information